DDInter1758 DDInter899
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Telithromycin {u} (Compound) resembles {v} (Compound) Azithromycin
Telithromycin {u} (Compound) binds {v} (Gene) CYP1A2
Telithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Ketolides
Telithromycin {u} (Compound) causes {v} (Side Effect) Bundle branch block
Telithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paricalcitol
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Telithromycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Telithromycin (Compound) resembles Azithromycin (Compound)
Telithromycin (Compound) binds CYP1A2 (Gene)
Telithromycin (Compound) is included by Ketolides (Pharmacologic Class)
Telithromycin (Compound) causes Bundle branch block (Side Effect)
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Telithromycin may lead to a major life threatening interaction when taken with Betrixaban
Telithromycin may lead to a major life threatening interaction when taken with Terfenadine
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin